Subjective effects of neuroleptics predict compliance

  • D. Naber
  • A. Walther
  • T. Kircher
  • D. Hayek
  • R. Holzbach


The low compliance of long-term neuroleptic treatment might be explained not only by extrapyramidal motor side effects (EPMS) but also by other subjective effects, hardly measurable by usual clinical rating scales. Therefore, a self-rating scale to measure subjective well-being on neuroleptics (SWN) was developed; first analyses indicate good practicability, reliability, validity and sensitivity. As the acute psychosis subsides, schizophrenic patients are able to fill out the questionnaire in 15–20 minutes.

Data, obtained from 216 remitted patients, showed that SWN correlates with psychiatrist’s ratings (PANSS), self-ratings of mood states (POMS, SDS, BfS) and EPMS; but variables explained only 19–47% of SWN variance. A repeated application after 3 months in 53 patients did not show any altered SWN in those with constant neuroleptic medication. Marked alterations were noted if dosage or drug was changed. SWN in 28 patients, treated with clozapine because of therapy resistance or major side-effects, was despite of the negative selection, significantly better (t=2.34, p =.02) than in 38 patients under classical neuroleptics. Moreover, already at discharge, patients who 4–6 months later were non-compliant (n=14), differed significantly (t=2.31, p =.02) in SWN, but not in BPRS or PANSS from those who remained compliant (n=34).

These data agree with clinical experience and show that SWN is a useful tool to investigate a hitherto neglected psychopathological dimension. The early detection of major subjective effects of neuroleptics might be helpful in identifying patients at risk of noncompliance. In these patients, strategies such as depot-injection, reduction of dosage or change of medication should be considered.


Negative Symptom Schizophrenic Patient Subjective Effect Neuroleptic Drug Neuroleptic Treatment 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Awad AG (1993) Subjective response to neuroleptics in schizophrenia. Schizophr Bull 19:609–618.PubMedGoogle Scholar
  2. Awad AG, Hogan TP (1994) Subjective response to neuroleptics and quality of life — implications for treatment outcome. Acta Psychiatr Scand 89[Suppl 380]:27–32.CrossRefGoogle Scholar
  3. Axelrod S, Wetzler S (1989) Factors associated with better compliance with psychiatric aftercare. Hosp Commun Psychiatry 40:397–401.Google Scholar
  4. Bandelow B, Müller P, Gaebel W, Köpcke W, Linden M, Müller-Spahn F, Pietzcker A, Reischies FM, Tegeler J (1990) Depressive syndromes in schizophrenic patients after discharge from hospital. Eur Arch Psychiatry Clin Neurosci 140:113–120.CrossRefGoogle Scholar
  5. Bandelow B, Müller P, Frick U, Gaebel W, Linden M, Müller-Spahn F, Pietzcker A, Tegeler J (1992) Depressive syndromes in schizophrenic patients under neuroleptic therapy. Eur Arch Psychiatry Clin Neurosci 141:291–295.CrossRefGoogle Scholar
  6. Barnes TR, Curson DA, Liddle PF, Patel M (1989) The nature and prevalence of depression in chronic schizophrenic in-patients. Br J Psychiatry 154:486–491.PubMedCrossRefGoogle Scholar
  7. Belmaker RH, Wald D (1977) Haloperidol in normals. Br J Psychiatry 131:222–223.PubMedCrossRefGoogle Scholar
  8. Brenner HD, Böker W, Rui C (1986) Subjektive Neuroleptikawirkung bei Schizophrenen und ihre Bedeutung für die Therapie. In: Hinterhuber H, Schubert H, Kulhanek F (Hrsg) Seiteneffekte und Störwirkungen der Psychopharmaka. Schattauer, Stuttgart, S 97–107.Google Scholar
  9. Brown SL, Sweeney DR, Schwarz GE (1979) Differences in self-reported and observed pleasure in depression and schizophrenia. J Nerv Ment Dis 167:410–415.PubMedCrossRefGoogle Scholar
  10. Craig TJ, Van Natta PA (1976) Recognition of depressed affect in hospitalized psychiatric patients: staff and patient perceptions. Dis Nerv Syst 37:561–566.PubMedGoogle Scholar
  11. Craig TJ, Richardson MA, Pass R, Bregman Z (1985) Measurement of mood and affect in schizophrenic inpatients. Am J Psychiatry 142:1272–1277.PubMedGoogle Scholar
  12. Diamond R (1985) Drugs and the quality of life: the patient’s point of view. J Clin Psychiatry 46:29–35.PubMedGoogle Scholar
  13. Emerich DF, Sanberg PR (1991) Neuroleptic dysphoria. Biol Psychiatry 29:201–203.PubMedCrossRefGoogle Scholar
  14. Ernst K (1954) Psychopathologische Wirkungen des Phenothiazin-Derivates “Largactil” (=“Megaphen”) im Selbstversuch und bei Kranken. Arch Psychiat Z Neurol 192:573–590.CrossRefGoogle Scholar
  15. Gebhardt R (1972) Veränderungen der subjektiven Befindlichkeit psychotischer Patienten unter neuroleptischer Therapie. Pharmakopsychiat 5:295–300.Google Scholar
  16. Hare EH, Willcox DRC (1967) Do psychiatric inpatients take their pills? Br J Psychiatry 113:1435–1439.PubMedCrossRefGoogle Scholar
  17. Heimann H, Witt PN (1955) Die Wirkungen einer einmaligen Largactilgabe bei Gesunden. Monatsschr Psychiat Neurol 129:104–128.CrossRefGoogle Scholar
  18. Heinrich K (1967) Zur Bedeutung des postremissiven Erschöpfungs-Syndroms für die Rehabilitation Schizophrener. Nervenarzt 38:487–491.PubMedGoogle Scholar
  19. Helmchen H, Hippius H (1969) Pharmakogene Depressionen. In: Hippius H, Seibach H (Hrsg) Das depressive Syndrom. Schattauer, München, S 443–448.Google Scholar
  20. Hogan TP, Awad AG, Eastwood R (1983) A self report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 13:177–183.PubMedCrossRefGoogle Scholar
  21. Jaeger J, Bitter I, Czobor P, Volavka J (1990) The measurement of subjective experience in schizophrenia: the subjective deficit syndrome scale. Comp Psychiat 31:216–226.CrossRefGoogle Scholar
  22. Johnson DAW (1977) Practical considerations in the use of depot neuroleptics for the treatment of schizophrenia. Br J Hosp Med 17:564–569.Google Scholar
  23. Johnson DAW (1981) Studies of depressive symptoms in schizophrenia. The prevalence of depression and its possible causes. Br J Psychiatry 139:89–101.PubMedCrossRefGoogle Scholar
  24. Knights A, Hirsch SR (1981) ‘Revealed’ depression and drug treatment for schizophrenia. Arch Gen Psychiatry 38:806–811.PubMedCrossRefGoogle Scholar
  25. Liddle PF, Barnes TRE (1988) The subjective experience of deficits in schizophrenia. Comp Psychiat 29:157–164.CrossRefGoogle Scholar
  26. Maurer Y, Dittrich A (1979) Vergleich von Selbst-und Fremdbeurteilung bei schizophrenen Patienten. Pharmakopsychiat 12:375–382.CrossRefGoogle Scholar
  27. Möller HJ, v. Zerssen D (1981) Depressive Symptomatik im stationären Behandlungsverlauf von 280 schizophrenen Patienten. Pharmacopsychiat 14:172–179.CrossRefGoogle Scholar
  28. Naber D, Holzbach R, Perro C, Hippius H (1992) Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry 160[Suppl 17]:54–59.Google Scholar
  29. Prosser ES, Csernansky JG, Kaplan J, Thiemann S, Becker TJ, Hollister LE (1987) Depression, parkinsonian symptoms, and negative symptoms in schizophrenics trated with neuroleptics. J Nerv Ment Dis 175:100–105.PubMedCrossRefGoogle Scholar
  30. Rifkin A, Quitkin F, Klein DF (1975) Akinesia. A poorly recognized drug-induced extrapyramidal behavioral disorder. Arch Gen Psychiatry 32:672–674.CrossRefGoogle Scholar
  31. Selten JP, Sijben NES, van den Bosch RJ, Omloo-Visser J, Warmerdam H (1993) The subjective experience of negative symptoms: a self-rating scale. Comp Psychiat 34:192–197.CrossRefGoogle Scholar
  32. Van Putten T (1974) Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 31:67–72.PubMedCrossRefGoogle Scholar
  33. Van Putten T, May PR (1978) ‘Akinetic depression’ in schizophrenia. Arch Gen Psychiatry 35:1101–1107.PubMedCrossRefGoogle Scholar
  34. Van Putten T (1978) Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry 35:477–480.PubMedCrossRefGoogle Scholar
  35. Wilson JD, Enoch MD (1967) Estimation of drug rejection by schizophrenic inpatients with analysis of clinical factors. Br J Psychiatry 113:209–211.PubMedCrossRefGoogle Scholar
  36. Windgassen K (1992) Treatment with neuroleptics: the patient’s perspective. Acta Pychiatr Scand 86:405–410.CrossRefGoogle Scholar
  37. Wise RA (1991) Neuroleptic-induced anhedonia. Recent studies. In: Tamminga CA, Schulz SC (eds) Advances in neuropsychiatry and psychopharmacology, vol I. Schizophrenia research. Raven Press, New York, pp 323–331.Google Scholar

Copyright information

© Springer-Verlag Wien 1994

Authors and Affiliations

  • D. Naber
    • 1
    • 2
  • A. Walther
    • 1
  • T. Kircher
    • 1
  • D. Hayek
    • 1
  • R. Holzbach
    • 1
  1. 1.Department of PsychiatryUniversity of MunichGermany
  2. 2.Department of PsychiatryUniversity of MunichMunichGermany

Personalised recommendations